



INTERNATIONAL REGULATION OF BIOTECHNOLOGY:
PROBLEMS AND PROSPECTS
Introduction
Of the issues that confront modem science and
the imperatives for development and human
progress today, none is more controversial than
biotechnology. As one author notes, within 'a few
short decades, the powerful means of biotechnolo-
gy have revolutionized medicine, agriculture and
environmental protection". The potential implica-
tions of biotechnology transcend science and the
environment and impact directly on the liberalisa-
tion of international trade, the protection of intel-
lectual property rights, the right of self determina-
tion of indigenous populations and as custodians
and owners of centres of biodiversity, and indeed on
international relations generally. Advocates of
biotechnology argue that the modification of the
genetic make- up of living organisms is nothing
new and that biotechnology has been part of
human agricultural practices for centuries. Given
its potential financial benefits, business executives
in the biotechnology industry routinely talk up its
virtues as the possible panacea to the starving mil-
lions of the world, notwithstanding the general
agreement that the full effect of biotechnology on
humans and the environment is yet unknown.
Advocates of the precautionary principle, on the
other hand argue that today, the principle is an
essential component of environmental policy and
part of international law and that the principle
should inform any regulatory approach to biotech-
nology. While opinions vary about the utility and
indeed the propriety of biotechnology, there is a
general consensus that biotechnology is set to
shape the future of mankind in the coming
decades. In spite of its potential impact, biotech-
nology has received relatively little attention from
international lawyers. The little international 'law'
there is on the issue is confined to a few 'soft law'
instruments. Questions of biotechnology feature
more as national issues meriting national regula-
tion. Where such questions have attracted interna-
tionallegal attention as in international trade dis-
putes, the issue has not been on the propriety of
biotechnology regulation as such. It has generally
centred on its impact on the freedom of trade. The
objective in this paper is to examine the issue as to
whether biotechnology is a legitimate subject for
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international regulation. The paper also evaluates
the normative scope for any possible international
regulatory framework for biotechnology.
Biotechnology as an international issue
International law is concerned with the regula-
tion of the conduct of states in their international
relations. It also regulates the conduct of other sub-
jects in the international legal system. In this
respect international law also seeks to regulate
national conduct on issues which are transnational
in character or are of international concern. What is
it about biotechnology then that warrants interna-
tional regulation? Biotechnology involves scientif-
ic technology that uses biological systems, living
organisms, or related derivatives to make or modify
products or processes for specific use. By its very
nature, biotechnology begins and appears as a
localised or national industrial issue. In spite of its
'localised' looks, the essence of biotechnology has
considerable international implications which war-
rant international attention and regulation for sev-
eral reasons.
International equity
Advocates of biotechnology argue that if allowed
to develop, genetically modified organisms could be
introduced into the market place for medical, phar-
maceutical, agricultural, alternative fuels, and
even for the protection of the environment itself. In
the field of agriculture, biotechnology has the
potential to alleviate a significant proportion of the
problems of starvation that persist in many parts of
the world and improve human lives particularly in
the developing world. But if indeed biotechnology
has this potential, and it does, should the interna-
tional community permit only the few companies
of technologically rich countries to control such an
important tool? While biotechnology itself is not a
global resource, it is a tool or an avenue with impor-
tant implications for global resources. It is thus
arguable that the philosophy underpinning the
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concept of the Common Heritage of Mankind (CHM)
which emerged in later of part of the twentieth cen-
tury could be applied to biotechnology-, The UN
General Assembly adopted Resolution 2749in 1970,
declaring the CHM as the primal principle govern-
ing the exploitation of the international seabed.
The CHMconcept was thereafter given legal status
in the 1982Law of the Sea Convention (entered into
force November 1994) as well as in the earlier 1972
UNESCOConvention for the Protection of the World
Cultural and Natural Heritage and in the 1979Moon
Treaty (both already in force). The CHMas put for-
ward by its proponents involve five basic pillars: the
exclusion of sovereignty or appropriation of the
resources of the deep seabed, shared management,
the management of the resources for the benefit of
mankind, the exclusive use of the resources for
peaceful purposes and the international protection
of the resources. The essence of the CHMconcept is
that resources of global significance cannot and
should not be left for appropriation by the rich.
Biotechnology is not a resource in its own right, but
like the deep seabed, it provides an important
access to resources that have the potential to
impact on humanity. In this regard, the application
of the CHM concept to biotechnology finds a ratio-
nal foundation.
The idea of applying the concept of CHM to
biotechnology and related issues is not new. In the
late 1980s developing countries sought to apply the
CHMconcept to biotechnology., Hhowever, in view
of the location of most of the world's 'centers ofbio-
diversity' in the developing countries, in 1991devel-
oping states pushed to revise the International
Undertaking on Plant Genetic Resourcest, so that
the concept of 'common heritage" was limited by
the sovereignty of states over their plant genetic
resources, as well as to by the rights of breeders
and farmers.s Later in 1997Universal Declaration
on the Human Genome and Human Rights stipu-
lated that: "[t)he human genome underlies the fun-
damental unity of all members of the human fami-
ly, as well as the recognition of their inherent dig-
nity and diversity't.f It further provided that the
human genome is 'the heritage of humanity". More
significantly, Article 4 of the Declaration also pro-
vides that "[t)he human genome in its natural state
shall not give rise to fmancial gains".
The application of CHM to biotechnology would
not, and need not preclude the patenting of drugs
and new products that emerge from biotechnology.
The rationale for application of CHM is to ensure
that access to the mysteries of genetics is free and
open to all and for the benefit of mankind.
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The environmental dimension: genetic pollution
Modem biotechnology is not only complex in its
sophisticated manipulation of genetics to created
new product; it is also a potentially perilous jour-
ney into uncharted waters. While advocates scorn
at the precautionary principle and use the principle
of scientific certainty as a shield from their oppo-
nents, the reality still remains that biotechnology
carries the risk of 'genetic pollution'. The issue is
well summed in the view that:
concerns arise about the potential for genetic
engineering to cause transnational catastrophic
harm (such as destabilizing a region's biosphere
through "genetic pollution"). Fears of catastrophic
harm caused by biotechnology raise questions
about who will bear the ultimate responsibility if
such an event were to occur. Finally, there are long-
term concerns about whether the widespread use of
genetically modified products could accelerate the
decline in global biological diversiryf
The 'unity' of the global environment clearly sug-
gests that genetic pollution in a particular region of
the world is not necessarily a localized issue. On the
contrary, it is an issue in which the international
community has legitimate interest that warrants
an international approach in regulation.
The international trade dimension
There are no accepted universal international
standards for biotechnology particularly in agricul-
ture. Given the concerns about the unknown
impact of genetically modified products on the
environment and for human health, many coun-
tries regard such products with suspicion and scep-
ticism. While TtheWTO rules permit the restric-
tion of imports on health environmental grounds,
it is not clear whether a member trading nation can
impose restrictions on genetically modified prod-
ucts in the absence of any proof that such products
cause any harm to consumers or the environment.
2 On the concept of the Common heritage of Mankind,
see generally Kemal Baslar The Concept of the Common
Heritage of Mankind in International Law (Brill1998).
3 For a commentary on the legal issues on the
Undertaking, see generally Bordwin H., The Legal and
Political Implications of the International Undertaking
on Plant Genetic Resources, 12 Ecology Law Quarterly
Vol. 12, 1053 (1985)
4 Rose, G, 'International Regimes for the Conservation
and Control of Plant Genetic Resources, in
International Law and the Conservation of Biological
Diversity
5 Article 1
6 Murphy, S. Biotechnology and International Law,
Harvard Iournal ofinternational Law, Vol. 42 (2001), 47.
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Neither is it clear whether existing international
trade rules require labelling to notify consumers
that a particular product is genetically engineered
or modified. The development of a comprehensive
international regime on biotechnology would help
to establish the guidelines to assist with trade
issues involving genetically modified products.
Inherent transnational character orbiotechnology policy issues
While local or national in character, biotechnol-
ogy policy issues have an intrinsic international
character. One authors sums up the international
elements in this observation:
As xenotransplants become more common, national
regulations maybe developedin somestates to prevent
animal viruses from spreading to humans. However,if
comparable regulations do not exist in other states,
leading to the risk of such viruses originating else-
where and then traveling to the highly regulated
states, then the national regulations will be under-
mined. In the field of immigration and refugee law, if
the use ofbiotechnologyformedical treatments in one
group of states vastly outpaces development in other
states, a new category of persons known as "medical
refugees" may emerge. Doctorsmay also somedaybe
able to screen individuals geneticallyfor their disposi-
tion to engage in criminal behavior,which may tempt
legislators to use this information to deny the admis-
sion of refugees on grounds ofnational security or safe-
ty. At the furthest extreme, if human doning is not
banned by some states, how should international law,
including human rights law, treat humans that are
cloned, or (dealwith) hybridmammals created in these
states??
The current international frame work for
regulation Of biotechnology
There is no single comprehensive international
instrument that regulates biotechnology and
addresses concerns that are generally levelled
against biotechnology. The existing law comprises
a mosaic of mostly soft law instruments that seem
to lack focus. It is possible to group the existing
instruments into four broad categories that encom-
pass: human rights protection, intellectual proper-
ty rights protection, the protection of the environ-
ment and agriculture and novel food products. In
this section we will examine briefly the instru-
ments that make up the regulatory regime.
The Human rights instruments
UNESCODeclaration on the Human Genomeand Human
Rights
The Universal Declaration on the Human
Genome and Human Rights was adopted by unani-
mous vote at the 29th session of UNESCO'sGeneral
Conference on 11 November 19971. It was subse-
quently endorsed by the United Nations General
Assembly in 19989. In 1999, UNESCO adopted
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Guidelines for the Implementation for the
Declaration. The central element of the Declaration
is its affirmation of the human rights of the indi-
vidual and the primacy of the human rights, fun-
damental freedoms and human dignity and over
'research applications concerning the human
genome, in particular in the fields of biology,
genetics and medicine'. 10The notion of human dig-
nity is central to the Declaration. Human dignity
concerns the intrinsic character of the human per-
son as such and the essence or value of the individ-
ual as a part of the human species. The focus of the
Declaration on human dignity however defin.ed is
thus significant".
In terms of regulation, the Declaration provides
in Article 11 that:
Practiceswhich are contrary to human dignity, such
as reproductive cloning of human beings, shall not be
permitted. States and competent international organi-
zations are invited to co-operate in identifying such
practices and in taking, at national or international
level, the measures necessary to ensure that the prin-
ciplesset out in this Declarationare respected.
While stating that practices such as human
cloning shall not be permitted, the Declaration
does not go any further to provide any concrete
directions for signatories. With statements such
as: 'states shall take appropriate measures' or
'steps', the Declaration provides little or no founda-
tion for a regulatory framework. The Declaration is
well known and referred to frequently in human
genome discussions. This notwithstanding the
instrument as a 'declaration' is not in itself legally
binding.
UNESCODeclarationon Human GeneticData
The Declaration adopted in 2003 aims to 'ensure
the respect of human dignity and protection of
human rights and fundamental freedoms in the
collection, processing, use and storage of human
genetic data, human proteomic data and of the bio-
logical samples from which they are derived'12
Article 19 provides for the sharing of the benefits
arising from human genetic data 'in accordance
with domestic law or policy and international





11 For a commentary on the Declaration see TAYLOR,A
Globalization and Biotechnology: UNESCOand an
International Strategy to AdvanceHuman Rights and
PublicHealth, AmericanJournal ofLawandMedicine,
(1999),n° 4, p. 479-541
JIBL Vol 02 I 2005
InternatiQrlal Regulation Of BiQte<;hnology:Problems.~l1d Prospects NOTES
Human Genome and Human Rights, this
Declaration provides no binding legal obligations.
United Nations Declaration on Human Cloning
In March 2005, the United Nations General
Assembly adopted Resolution 10333 on human
cloning. The resolution was the result of a long and
controversial debate in the Assembly. Unlike the
unanimous declaration in the UNESCO General
Conference, this resolution was adopted by 84 in
favour to 34 against, with 37 abstentions. The sub-
stantive element in the Declaration is that proba-
tion of 'all forms of human cloning inasmuch as
they are incompatible with human dignity and the
protection of human life' While the Declaration is
not legally binding, the strong opposition it
attracted provides an important insight into the
difficulties of adopting an international instru-
ment on the issue of cloning. In explaining why
China voted against the Declaration, the Chinese
delegate explained that 'different countries varied
in their understanding of the text's inherent
moral, ethical and religious aspects, and it was
regrettable that the Declaration failed to give effect
to the concerns of those countries. He argued that
the prohibitions contained in the text could be mis-
understood as covering all forms of cloning .13
Council ofEurope's Convention for the Protection ofHuman
Rights and Dignity of the Human Being with Regard to the
Application of BiologV and Medicine: Convention on Human
Rights and Biomedicine
This is the first and indeed only attempt to estab-
lish a binding European legal instrument that cov-
ers not all but at least some of the core areas of
medicine. Unlike the United Nations and UNESCO
instruments, the Council of Europe Convention on
Human Rights and Biomedicine is legally binding.
Parties to the Convention undertake to 'protect the
dignity and identity of all human beings and guar-
antee everyone, without discrimination, respect
for their integrity and other rights and fundamen-
tal freedoms with regard to the application of biol-
ogy and medicine'.14 Article 2 emphases the prima-
cy of human dignity over the 'sole interest of soci-
ety or science'. Article 11 prohibits discrimination
on the basis of genetic make up while Article 12 and
13 restrict predictive genetic tests and intervention
on the human genome respectively.
The Convention is a 'framework' instrument and
leaves room for more specific instruments in the
nature of 'additional protocols' to deal with more
specific issues: So far three additional protocols
have been adopted with a fourth on human genet-
ics to be developed later. The current additional
protocols are:
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(1) The Additional Protocol to the Convention on
Human Rights and Biomedicine on the
Prohibition of Cloning Human Beings
The substantive section of this instrument is
Article 1which provides in very explicit terms as
follows:
1. Any intervention seeking to create a human
being genetically identical to another human
being, whether living or dead, is prohibited.
2. For the purpose of this article, the term
human being "genetically identical" to
another human being means a human being
sharing with another the same nuclear gene
set.
As noted in the Explanatory Report to the
Protocol, the instrument 'does not take a specific
stand on the admissibility of cloning cells and tis-
sue for research purposes resulting in medical
applications'vs as such. However, the general
tenure of the provisions seems to admit that
'cloning as a biomedical technique is an important
tool for the development of medicine, especially for
the development of new therapies'. The
Explanatory Report therefore makes the point that
the 'provisions in [the] Protocol shall not be under-
stood as prohibiting cloning techniques in cell biol-
ogy'.
(2) The Additional Protocol to the Convention on
Human Rights and Biomedicine on the
Transplantation of Organs and Tissues of
Human Origin
This Protocol applies to the transplantation of
organs and tissues of human origin carried out for
therapeutic purposes. Its provisions applicable to
tissues also apply to cells, including haematopoiet-
ic stem cells.16 However, the Protocol does not
apply reproductive organs and tissue and neither
does it apply to embryonic or foetal organs and tis-
sues or to blood and blood derivatives.v
While Article 22 prohibits 'organ and tissue traf-
ficking', Article 21 provides that the 'human body
tz Art.«.
13 UN News release: httpr/ywww.un.org/News/Press/
dOCS/200S/ga10333.doc.htm (23MaY2oos)
14 Art. 1
15 Explanatory Report, Additional Protocol to the
Convention on Human Rights and Biomedicine on the








and its parts shall not, as such, give rise to financial
gain or comparable advantage'. Given the ban on
organ and tissue trafficking, it is understandable
that the Protocol further prohibits the making of
'financial gain or comparable advantage' from the
human body and its parts'. The question of finan-
cial gain is however very problematic. The Protocol
does not define 'financial gain or comparable advan-
tage'. It is to be noted that Article 21 permits 'pay-
ments which do not constitute a financial gain or a
comparable advantage, in particular:
- compensation of living donors for loss of
earnings and any other justifiable expenses
caused by the removal or by the related med-
ical examinations;
- payment of a justifiable fee for legitimate
medical or related technical services rendered
in connection with transplantation;
- compensation in case of undue damage
resulting from the removal of organs or tis-
sues from living persons
(3) The Additional Protocol to the Convention on
Human Rights and Biomedicine, concerning
Biomedical Research
This Protocol covers the full range of research
activities in the health field involving 'interven-
tions' on human beings. However it does not apply
to research on embryos in vitro; it applies to
research on foetuses . and embryos in vivo. IS It
requires any research to be 'scientifically justified',
and to 'meet generally accepted criteria of scientific
quality and to be carried out in accordance with rel-
evant professional obligations and standards under
the supervision of an appropriately' qualified
researcher'.(Article 8). The protocol further defines
the conditions to be fulfilled.in instances where the
research involves persons who are not capable or
able to provide valid and informed consent, and
groups such as prisoners or expectant or nursing
mothers.
In spite of its 'hard law' provisions, the Protocol
also contains some soft law elements. For instance
Article 6 provides that '[r]esearch shall not involve
risks and burdens to the human being dispropor-
tionate to its potential benefits'. (emphasis added).
It further provides that 'where the research does not
have the potential to produce results of direct bene-
fit to the health of the research participant, such
research may only be undertaken if the research
entails no more than acceptable risk and acceptable
burden for the research participant'.
The pProtocol anticipates developments in sci-
ence. Article 35 thus provides that '[i]n order to
monitor scientific developments, the ... Protocol
shall be examined within (the relevant Committee)
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... no later than five years from the entry into force
... and thereafter at such intervals as the Committee
may determine.
Biodiversity and the Protection of the Environment
There is a number of instruments which directly
relate to biodiversity and the environment in so far
as biotechnology is concerned. These include:
The Convention on Biological Diversity
Adopted in 1992, the Biodiversity Convention is
the most comprehensive international instrument
relating to the conservation of biodiversity, The
emphasis of the instrument however is not on
biotechnology as such. The objectives of the
Convention are stated as 'the conservation of bio-
logical diversity, the sustainable use of its compo-
nents and the fair and equitable sharing ofthe ben-
efits arising out of the utilization of genetic
resources, including by appropriate access to genet-
ic resources and by appropriate transfer of relevant
technologies, taking into account all rights over
those resources and to technologies, and by appro-
priate funding'.19 While Article 19 of the Convention
specifically refers to issues of biotechnology and
biosafety, the provisions are largely in the nature of
'soft law'. For instance the Contracting Parties
undertake to 'provide for the effective participation
in biotechnological research activities' particularly
by developing countries. They· also undertake to
adopt 'all practicable measures to promote and
advance priority access on a fair and equitable basis
by Contracting Parties,.especially developing coun-
tries, to the results and benefits arising" from
biotechnologies based upon genetic resources pro-
vided by those Contracting Parties'. On the specific
issue of safety, the Convention only provides for the
parties to 'consider the need for and modalities of a
protocol setting out appropriate procedures, includ-
ing, in particular, advance informed agreement, in
the field of the safe transfer, handling and use of
any living modified organism resulting from
biotechnology that may have adverse effect on the
conservation and sustainable use of biological diver-
sity:
Cartagena Protocol on Biosafety
Adopted in pursuance of the reactionary princi-
ple under Principle 15 of the Rio Declaration, the
objective of this Protocol is 'to contribute to ensur-
ing an adequate level of protection in the field of the
safe transfer, handling and use of living modified
18Article 2
19 Article 1.
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organisms resulting from modern biotechnology
that may have adverse effects on the conservation
and sustainable use of biological diversity, taking
also into account risks to human health, and specif-
ically focusing on transboundary movements.P?
The Protocol covers the 'transboundary movement,
transit, handling and use of all living modified
organisms that may have adverse effects on the con-
servation and sustainable use of biological diversi-
ty, taking also into account risks to human health'
but excludes the 'transboundary movement of liv-
ing modified organisms which are pharmaceuticals
for humans that are addressed by other relevant
international agreements or organisations's- Apart
from risk managements- and risk assessment-s
issues, the Protocol also makes provisions for 'han-
dling transporting, packaging and identification of
modified organisms in order to avoid adverse effects
on the conservation and sustainable use of biologi-
cal diversity'.24 The Protocol also creates the
Biotechnology Clearing House, in order to facilitate
the exchange of information on Living Modified
Organisms and to assist countries to implement the
Protocol.
Law of the Andean Community
The Andean Community is a sub-regional organi-
zation that comprises South America: Bolivia,
Colombia, Ecuador, Peru and Venezuela created
through the Cartagena Agreement. ,In 2000 The
Community adopted 'Decision 486', which sets out
common rules for the granting, implementation
and enforcement of a wide range.of IPRs.iIi the five
Member states .with direct reference to the
Convention on Biological Diversity,
International Plant Protection Convention
Originally adopted in 1951and revised in 1997,the
International Plant Protection Convention (IPPC)
the main objective of this instrument isaims to
implement a secure joint and effective action to
prevent the spread and introductions of pests of
plants and plant products, and to promote appro-
priate measures for their control. It is a multilater-
al agreement which is legally binding.
Foodand Agriculture
The main international instrument regarding
biotechnology issues in food and agriculture is the
International Treaty on Plant Cenetic Recourses for
Food and Agriculture. While Thethe preamble of
the instrument recognisesrecognizes 'that plant
genetic resources for food and agriculture are the
raw materials indispensable for crop genetic
improvement, whether by means of farmers' selec-
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tion, classical plant breeding or modem biotech-
nologies, and are essential in adapting to unpre-
dictable environmental changes and future human
needs'. However, the focus of the treaty is on plant
genetic resources as such and not on biotechnology.
The most comprehensive international instru-
ments concerning biotechnology in food and agri-
culture are the several European Directives and
Regulations. For example, Regulation (EC) No
1830/2003 of the European Parliament and of the
Council provides 'a framework for the traceability of
products consisting of or containing genetically
modified organisms (CMOs), and food and feed pro-
duced from CMOs, with the objectives of facilitat-
ing accurate labelling, monitoring the effects on
the environment and, where appropriate, on
health, and the implementation of the appropriate
risk management measures including, if necessary,
withdrawal of products', (Article 1) The Regulation
applies at all stages of the placing on the market,
to: (a) products consisting of, or containing, CMOs,
placed on the market in accordance with
Community legislation; (b) food produced from
CMOs, placed on the market in accordance with
Community legislation; (c) feed produced from
CMOs, placed on the market in accordance with
Community legislation.(Article 2). Commission
Regulation (EC)No49/2000 of 10 January 2000 deals
with issues of labeling of food products and the
establishment of a de minimis threshold forrthe
adventitious presence in food ingredients of mater-
ial derived from the certain genetically modified
food products. Regulation (EC)No 1829/200J 0[;22
September 2003 on genetieally modified food and
feed provides the basis for ensuring a high level of
protection of human life and health, animal health
and welfare, environment and consumer interests
in relation to genetically modified food and feed,
whilst ensuring the effective functioning of the
internal market; and lays down Community proce-
dures for the authorisation and supervision of
genetically modified food and feed. It further deals
with labelling of genetically modified food and
feed. Regulation (EC)No 258/97 (concerning novel
foods and novel food ingredients) applies foods and
food ingredients containing or consisting of geneti-










Since biotechnology inherently involves the use
of biological systems, living organisms, or related
derivatives to make or modify products or process-
es, it invariably has intellectual property implica-
tions. Article 27 of the WTO Agreement on Trade-
Related Aspects of Intellectual Property Rights
(TRIPSAgreement) excludes patentability for diag-
nostic, therapeutic and surgical methods for the
treatment of humans or animals. It allows for the
exclusion of 'plants and animals other than micro-
organisms, and essentially biological processes for
the production of plants or animals other than non-
biological and microbiological processes.' However,
it permits Members to 'provide for the protection of
plant varieties either by patents or by an effective
sui generis system or by any combination thereof.'
The European Directive 98/44/EC of July 1998 also
deals with the 'legal protection of biotechnological
inventions'.
The normative focus of requlation in biotech-
nology
What is the normative issue in the regulation of
biotechnology? There is confusion in international
law as the focus of regulation. It is not clear if the
focus should be on intellectual property protection
or public accountability. Asa logical development of
man's creative abilities, biotechnology offers an
unparalleled potential for mankind. It represents
an excellent avenue that can be applied to many
areas of food and agriculture, medicine and the
invention of new drugs. It offers tremendous poten-
tial to address real problems facing the many mil-
lions of people particularly in the developing coun-
tries who face constant starvation. But like most
other phenomena known in human history, the
unregulated application of biotechnology has
potential adverse implications also.
If one makes intellectual property rights protec-
tion the focus in biotechnology, then the claim by
biotechnology industries that their methods and
products are simply innovations and amount to no
more than man's evolutionary and sometimes revo-
lutionary approaches to inventions and progress are
correct. The issue of intellectual property protec-
tion cannot and should be dismissed too lightly. As
noted earlier, to the extent that biotechnology
involves the manipulation of biological systems,
living organisms, or related derivatives to make or
modify products, it invariably involves inventions
and matters issues of intellectual property rights.
Once we accept the need to protect intellectual
property rights generally in other areas of human
252
Sam Blay
activity, then logically we must also accept the
right to protect new inventions through the use of
biotechnology.
On the other hand if one makes public account-
ability and regulation as the focus for regulation,
then the issues are quite different. The issue central
question becomes the scope and extent necessary to
regulate biotechnology without stifling human
progress and new inventions. The attraction of
making accountability the focus of regulation is
that it is capable of providing a better avenue for
balance between the competing demands of corpo-
rate profits through intellectual property rights
protection, and the need to ensure community pro-
tection through a credible system of transparency
and accountability.
Whatever focus one chooses as the basis of regu-
lation of biotechnology, the reality is that there is
no credible international instrument that regulates
biotechnology activities as such apart from the
European regulations and directives. Perhaps given
the history of Europe, the relative clarity with
which the Europeans have approached the question
of biotechnology is understandable. But their
approach must provide important lessons for the
rest of international community. The current inter-
national legal frame work for the regulation of
biotechnology is far from desirable. Apart from the
absence of any stringent system of accountability
on an international basis, the current regime lacks
a comprehensive or holistic approach. The reality
of biotechnology is that it is not only international
in character, but as the scientific knowledge of
mankind advances, so would the new biotechrolog-
ical inventions increase. Given the predictable
incremental advances in man's inventive ability,
there would seem to be an urgent need to develop
appropriate instruments that comprehemively
address the question of biotechnology in all aspects.
The development of the WTO Agreement ar.d its
related multilateral and plurilateral agreements
concerning all aspects of trade suggest clearly that
it is possible to adopt a comprehensive regime on
biotechnology. Indeed it is arguable that it is paten-
tially easier to develop a comprehensive trea:y on
biotechnology because most states have in place
national legislation that deals with some aspects of
biotechnology already, unlike what negotiators
would have encountered during the talks to dele lop
the WTO agreements. The prospects for a compre-
hensive international regulatory instrument on
biotechnology are rather good. The international
community must adopt an accountabilltv-oriented
focus for regulation and develop such an instru-
ment accordingly.
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